Skip to main content
. 2019 Apr 2;55(4):88. doi: 10.3390/medicina55040088

Table 1.

Characteristics of the control and study group according to sex, age, disease activity, medical therapies, and selected inflammatory and nutritional indices.

Parameter Controls CD Patients UC Patients p-Value
Number of cases 57 47 71
Sex (F/M) 27/30 23/24 31/40 0.837 Χ2
Age [years] 42 (35–50.4) 40 (30.6–42.7) 46 (36.1–50.2) 0.260 K
Active disease, n (%) - 37 (78.7) 30 (42.3%) <0.001 F
CS, n (%) - 20 (42.6) 23 (32.4) 0.329 F
AZA, n (%) - 19 (40.4) 15 (21.1) 0.037 F
BMI [kg/m2] 25 (21.7–28.2) 23.1 (21.4–24.7) 23.5 (22.4–24.6) 0.445 A
ALB [g/dL] 4.77 (4.7–4.9) a,b 4.23 (4.1–4.4) b,c (4.48 (4.4–4.6) a,c <0.001 A
hsCRP [mg/L] 1.84 (0.84–4.95) a,b 52.9 (17.4–99.3) c 25 (13.8–43.5) c <0.0001 K
HGB [g/dL] 13.2 (12.3–15) 12.1 (11.4–12.6) 12.8 (12.2–13.5) 0.084 K
Iron [μM] 18.6 (15.7–21.4) a,b 10.8 (8–12.5) b,c 15.5 (13.4–17.6) a,c <0.0001 K
ESR [mm/hr] 9 (7.2–15) a 20 (16.8–26.5) b 14.5 (11.7–22) 0.018 K
PLT [×103/mm3] 250 (216–320) a 367 (330–411) b,c 292 (276–316) a 0.011 K
WBC [×103/mm3] 6 (5.47–6.61) 6.35 (5.6–8.16) 6.4 (5.8–7.53) 0.474 K
IL-1 [pg/mL] 0.79 (0.31–1.71) 0.93 (0.59–1.37) 0.94 (0.7–1.41) 0.550 K
IL-6 [pg/mL] 0.77 (0.68–1.14) a,b 2.57 (1.83–3.84) c 1.99 (1.23–2.82) c <0.0001 K
TNF [pg/mL] 0.83 (0.4–1.44) 0.77 (0.37–1.04) 0.53 (0.35–0.94) 0.914 K

If not otherwise stated, data presented as medians with 95% CI. and data on BMI and ALB as means with 95% CI. CD, Crohn’s disease; UC, ulcerative colitis; F, females; M, males; CS, corticosteroids; AZA, azathioprine; BMI, body mass index; ALB, albumins; hsCRP, high-sensitive C-reactive protein; HGB, hemoglobin; ESR, erythrocyte sedimentation rate; PLT, platelets; WBC, white blood cell; IL-1; interleukin-1; IL-6, interleukin-6; TNF, tumor necrosis factor; a, significantly different from CD; b, significantly different from UC; c, significantly different from controls; Χ2, Chi-square test; F, Fisher’s exact test; K, Kruskal-Wallis H test. A, one-way ANOVA.